Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.
Official title: Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC: A Retrospective Multi-center Study (NeoR-World)
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
1500
Start Date
2022-01-01
Completion Date
2026-06-01
Last Updated
2023-08-03
Healthy Volunteers
Yes
Conditions
Interventions
Neoadjuvant immunochemotherapy
Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
Neoadjuvant chemotherapy
Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
Locations (1)
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China